Full-Time

Category & Shopper Manager

Shopper Science Lab

Deadline 8/28/26
Haleon

Haleon

10,001+ employees

Global consumer health care products company

No salary listed

London, UK

Hybrid

Hybrid role based at Haleon HQ in London, with occasional travel to local markets.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Sales
Branding/Brand Strategy
Marketing
Data Analysis

Get referred to Haleon

See people who can refer or advise you

Requirements
  • A Bachelor's degree is required.
  • Significant experience in category management, shopper insights, commercial, sales, or marketing roles, ideally within fast-moving consumer goods, consumer healthcare, or retail environments, is required.
  • Experience using shopper and customer insights to support commercial recommendations and decision-making is required.
  • Experience working in a matrixed environment is required.
  • Ability to deliver high-quality outputs with strong attention to detail.
  • Ability to build effective relationships across functions and markets.
  • Ability to use data and insight to support recommendations and decisions.
  • Ability to prioritise workload effectively and manage multiple projects simultaneously.
  • Ability to communicate clearly and confidently with customers and internal stakeholders.
  • Curiosity and a continuous learning mindset.
  • Ability to embrace change and adapt effectively in a fast-paced environment.
Responsibilities
  • Support the integration of shopper, customer, and retailer insights into category plans and customer initiatives.
  • Partner with OU and market teams to translate category and brand growth plans into retailer-relevant recommendations.
  • Support the localisation and implementation of category strategies across European markets.
  • Contribute to the development of core category growth tools and materials.
  • Support Perfect Shelf and execution excellence programmes through application of Shopper Science Lab capabilities.
  • Deliver customer engagement and retailer collaboration sessions within the Shopper Science Lab.
  • Support the design and execution of immersive Shopper Science Lab experiences that bring category strategies and insights to life.
  • Work with market teams to adapt Shopper Science Lab outputs and recommendations to local customer needs.
  • Share best practices and case studies across markets to drive consistency and learning.
  • Support capability-building activities that increase understanding and adoption of Shopper Science Lab tools and approaches.
  • Apply Shopper Science Lab tools and methodologies to generate shopper and customer insights.
  • Support shopper research projects that inform innovation, portfolio, and execution decisions.
  • Analyse shopper behaviour and translate findings into clear recommendations for category and commercial teams.
  • Support range, assortment, layout, and portfolio optimisation programmes.
  • Contribute to continuous improvement by identifying opportunities to enhance tools, capabilities, and ways of working.
Desired Qualifications
  • Experience in category management, shopper insights, commercial, sales, or marketing within fast-moving consumer goods, consumer healthcare, or retail environments is ideally preferred.

Haleon is a global consumer health company that develops and sells everyday health products under brands such as Sensodyne, Advil, and Centrum. Its products address oral care, pain relief, immunity, and general well-being, working through science-backed formulations people use daily. Haleon differentiates itself by being a focused, standalone consumer health business formed from GSK’s spin-off and built from leading brands through major acquisitions, operating at scale with a portfolio of category leaders and competing with peers like Kenvue and Procter & Gamble. Its goal is to help people take control of their daily health with trusted products, while expanding its global reach and investing in manufacturing capacity and brand development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Weybridge, United Kingdom

Founded

2022

Get referred to Haleon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 organic growth reached 2.6%; Q2 improved to 3.1% with North America rebound.
  • Emerging markets grew 6.3% in Q2 2026, led by China, India, and Latin America.
  • Haleon priced a $2 billion bond on August 13, 2026, refinancing March 2027 notes.

What critics are saying

  • Haleon terminated Eroxon U.S. rights on June 29, 2026 after slower-than-expected sales.
  • July 30, 2026 litigation revived claims over Advil Sinus maximum-strength labeling.
  • June 4, 2026 Gas-X recall and sub-4% growth against a 4%-6% target threaten valuation.

What makes Haleon unique

  • Haleon owns category-leading brands like Sensodyne, Advil, Panadol, and Centrum across 170 markets.
  • Its June 29, 2026 Microsoft partnership embeds AI across operations, data, and productivity.
  • Oral health innovation keeps driving share gains; H1 2026 oral health grew 7.3%.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Parental Leave

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Investegate
Aug 13th, 2026
Haleon prices $2B bond offering to repurchase 2027 notes

Haleon's US subsidiary, Haleon US Capital LLC, has launched and priced a $2 billion fixed-rate bond offering. The offering comprises three tranches: $600 million in notes maturing in 2029 with a 4.625% coupon, $600 million in notes maturing in 2031 with a 4.875% coupon, and $800 million in notes maturing in 2036 with a 5.375% coupon. The offering is scheduled to settle on 21 August 2026. Payment of principal and interest is fully guaranteed by Haleon plc. The company plans to use the net proceeds, together with cash on hand if necessary, to repurchase its outstanding $1,999,350,000 3.375% fixed rate senior notes due March 2027 and for general corporate purposes. Barclays Capital, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho Securities acted as joint book-running managers.

CCentral
Aug 4th, 2026
Daniela Cavinatto appointed general manager of Canada division for Haleon Canada.

Daniela Cavinatto appointed general manager of Canada division for Haleon Canada. Daniela Cavinatto joins the consumer health company with more than 25 years of international leadership experience. Haleon Canada has appointed Daniela Cavinatto as its new general manager of the Canada division. Cavinatto joins the consumer health company with more than 25 years of international leadership experience. In her new position, she will lead Haleon's Canadian operations as the company works to strengthen its market leadership and expand its portfolio of consumer health brands, including Advil, Sensodyne, and Centrum. Industry experience across global markets. Prior to joining Haleon, Cavinatto served as general manager, Canada for The LEGO Group. During her time there, she led business growth by redefining market strategy, strengthening customer partnerships, and optimizing commercial investments. Throughout her career, Cavinatto has held senior executive roles across North America, Latin America, and Europe. Her background spans general management, sales, marketing, customer development, eCommerce, retail operations, and supply chain. "Daniela is an accomplished business leader with a proven ability to unlock growth, navigate complexity and deliver results in dynamic markets," said Nathalie Gerschtein, the Haleon North America president. "Canada is an important growth market for Haleon, and Daniela brings the commercial acumen, global perspective and leadership experience needed to help us build on our momentum. I am delighted to welcome Daniela to our North American leadership team and look forward to working with her as we strengthen our trusted brand portfolio and advance our leadership in consumer health." Portfolio reach and growth strategy. Haleon's Canadian product lineup holds a strong presence across retail channels. According to the company, six in 10 Canadian households rely on at least one Haleon brand. As of last year, the 2025 Product of The Year lineup included Tums Chewy Bites with Gas Relief. Cavinatto noted that the reach of the company's product line made the role an exciting opportunity. "Throughout my career, I've been inspired by opportunities to transform businesses, accelerate growth and help teams achieve ambitious goals," Cavinatto said. "That's what makes this opportunity so compelling. Haleon's portfolio of brands is rooted in science and consumer understanding with six in 10 Canadian households relying on at least one of our iconic brands. To lead a business with this kind of reach and impact is a true privilege and an opportunity that deeply inspires me." She added that she looks forward to working with internal teams, retail customers, and commercial partners to support the company's continued growth and innovation across Canada.

Yahoo Finance
Aug 1st, 2026
Haleon H1 2026: Organic growth hits 3.1%, margins up 120bp as North America rebounds

Haleon reported H1 2026 results ending 30 July, showing improved organic sales growth of 3.1% in Q2, with volume and mix up 1.4%. North America delivered strong progress at 3.1% growth, driven by shelf resets, innovation, and e-commerce momentum. Operating margin improved 120 basis points at constant currency, supported by supply chain efficiency and gross margin expansion of 140 basis points. Emerging markets achieved 6.3% growth in Q2, with India and Latin America leading performance. EPS grew 12% in H1. However, respiratory health remained weak, reducing organic growth by 150 basis points. Europe proved challenging with only 0.4% growth, whilst Middle East markets including Dubai and Pakistan experienced significant declines. The company acknowledged performing below its 4–6% medium-term growth target, with particular gaps in Europe and the Middle East.

Sharecast
Jul 30th, 2026
Oral health drives first-half growth at Haleon.

Oral health drives first-half growth at Haleon. 368.40p. 11:52 30/07/26. Haleon reported first-half revenue of £5.60bn on Thursday, up 2.2% on a reported basis and 2.6% organically, with second-quarter organic growth improving to 3.1% as North America strengthened. 10,913.70. 5,926.86. 5,860.81. 24,761.16. 11:51 30/07/26. Adjusted operating profit rose 8.2% at constant currencies to £1.36bn and the adjusted operating margin increased to 24.3%, while adjusted diluted earnings per share rose 12% to 10.3p. Oral Health was the strongest category, with second-quarter growth of 6.2%, while emerging markets grew 6.3%. The consumer healthcare group reiterated its full-year guidance for organic revenue growth of 3% to 5% and high-single-digit adjusted operating profit growth at constant currencies. "We delivered a good first half performance in what remains a challenging consumer environment, with sequential improvement in Q2 and a more balanced price and volume/mix," said chief executive Brian McNamara. Haleon also raised its interim dividend 9% to 2.4p and said it had completed £457m of its planned £500m share buyback for 2026. At 0947 BST, shares in Haleon were down 2.03% at 372p. Reporting by Josh White for Sharecast.com.

KamCity
Jul 29th, 2026
Maker of Panadol launches new dual-action Pain Relief Tablets.

Maker of Panadol launches new dual-action Pain Relief Tablets. 29th July 2026 Haleon, the maker of Panadol, is expanding into the dual-action pain relief market with the launch of Panacombo Dual Action Pain Relief 200mg/500mg Film-coated Tablets (ibuprofen & paracetamol). The formulation of two pain-relieving ingredients is designed to be stronger and faster than ibuprofen alone, delivering effective pain relief from multiple pain types, including migraine, headache, backache, dental pain, period pain, joint or muscular pain, and aches linked with cold and flu. Haleon noted that Ibuprofen acid alone only provides effective pain relief in 37-45% of cases, while combining ibuprofen with paracetamol increases effectiveness to 67-70%, highlighting the enhanced pain relief achievable through a combined approach. Expanding the trusted Panadol range, Panacombo Dual Action Tablets are formulated to give your shoppers dual relief in one tablet. Paracetamol helps to block pain signals, and ibuprofen helps stop pain at the source. Monica Michalopoulou, Marketing Director at Haleon, said: "For 70 years, Panadol have been experts in pain relief, trusted to assist consumers with pain when needed. The launch of Panacombo, our dual-action pain-relief solution, expands our range of trusted products, and will offer retailers a strong proposition to help boost sales, encouraging shoppers to trade up and benefit from our trusted brand credentials." Panacombo Dual Action Tablets are rolling out in grocery stores at an RRP of £3.50. The launch will be supported by a wide-reaching consumer media activation and campaign later in the year.